We described a patient with Beckwith-Wiedemann syndrome associated with rhabdomyosarcoma (RMS), and renal cell carcinoma (RCC). Karyotypes of peripheral lymphocytes and RMS cells were normal. DNA analyses showed maternal loss of heterozygosity (LOH) at 1 l p 15 region in RMS but not in RCC. The insulin-like growth factor II gene (IGF2) was found to be expressed at a moderate level in RMS but not in RCC by in situ hybridization. Each of parental allele-derived IGF2 transcript was detected in RCC, while maternal allele-derived transcript was weak in RMS because of maternal LOH. These results suggest that (1) loss of imprinting (LOI) of IGF2 might be responsible for BWS, (2) on the other hand, LOI itself might not induce tumor occurrence in tissues where the control of tissue-specific expression of 1GF2 is maintained, (3) increased expression of IGF2 due to maternal loss of a putative controller gene for 1GF2 at l lp15 might predispose to sustaining tumorigenic mutations and tumor progression, (4) loss of a putative onco-suppressor gene at l lp15 might induce RMS occurrence. The cause of RCC was thought to be different from that of RMS.
INTRODUCTION
Beckwith-Wiedemann syndrome (BWS) is a congenital overgrowth syndrome, which is sometimes associated with embryonal tumors, such as Wilms tumor, rhabdomyosarcoma (RMS), hepatoblastoma and adrenal carcinoma (Cohen, 1989) . The BWS locus is localized to l lpl5, where the genes for insulin (INS) and insulinlike growth factor II (IGF2) are also mapped; the latter might be responsible for perinatal gigantism and visceromegaly in BWS. In sporadic cases of BWS, paternal uniparenta! disomy or partial trisomy of paternal origin involving an 11p15 region have been known (Henry et al., 1991; Mannens, 1991) , while the predominance of maternal transmission of the disease in familial BWS cases have been reported (Niikawa et al., 1986) . Moreover, there is evidence that IGF2 is maternally imprinted (paternally expressed) in both the mouse and the human (Rainier et al., 1993) . Therefore, a role of IGF2 in a cause of BWS and/or tumor occurrence or progression is highlighted.
Here, we describe a BWS patient who developed in a short period rhabdomyosarcoma and renal cell carcinoma, together with the results of cytogenetic and molecular analyses which confirmed loss of heterozygosity (LOH) for a part of l lp15 in the RMS cells.
MATERIALS AND METHODS

Patient.
The patient is a 3-year-old boy. He was born at the 37th week of gestation to non-consanguineous parents with a birth weight of 3,430 g (+ 1.3 SD). He suffered from tachypnea and feeding difficulty on day 1 and admitted to our hospital. He had a macroglossia, diastasis recti, hepatomegaly and hypoglycemia (20-30 mg/dl). Ear lobes were of normal appearance. He was diagnosed as BWS. At age 22 months, a lower abdominal mass was found and a needle biopsy revealed an embryonal type of rhabdomyosarcoma. The patient was treated according to the Intergroup Rhabdomyosarcoma Study (IRS) III protocol, then the tumor mass was subtotally resected, and irradiation was done to the peritoneal region during the surgical operation. At age 37 months during the following chemotherapy, another tumor was detected in the right kidney by computed tomography. The second tumor was totally removed and the same chemotherapy regimen has been going on. Pathological examination revealed that the second tumor was not a Wilms tumor but a renal cell carcinoma (RCC).
Chromosome analysis. Chromosome analyses with conventional and high resolution GTG-banding were done on cultured peripheral blood lymphocytes. As for RMS, a resected fresh tissue was minced with scissors and treated with a solution containing 0.8~ collagenase and 0.002~ DNase I for 15 rain. The cell pellet was washed with PBS and cultured for 10 days with the ES medium (Nissui) supplemented with 20~ FBS. G-banding chromosome analysis was performed in 20 metaphase cells. RCC tissue was not available for karyotype analysis.
Molecular analysis. DNA from peripheral blood leukocytes (PB) of patient and his parents and from the RMS tissue was digested with several endonucleases and analyzed with Southern hybridization. Probes used were genomic DNA for the tyrosine hydroxylase gene (TH), INS, and IGF2 (kindly given by Dr. G. I. Bell), c-H-ras (from JCRB) and DllS12 (kindly given by Dr. Y. Nakamura). Another part of DNA was used for a polymerase chain reaction (PCR) assay to detect microsatellite nucleotide repeat polymorphism and restriction fragment length polymorphisms (RFLPs) for TH (Human Gene Mapping 11,1991) , IGF2 (Ogawa et al., 1993a) , HI9 (Rainier et al., 1993; Matsumoto et aL, 1994a) , the Wilms tumor suppressor gene (WT1) (Zhang and Tycko, 1992; Matsumoto et al., 1994b) and DllS527 (Human Gene Mapping 11, 1991) . Each primer was synthesized by Gene Assembler Plus (Pharmacia LKB). PCR was done as described previously (Kinoshita et al., 1991) . Single strand conformation polymorphism (SSCP) analysis was also done for WT1, H19, and INS. Reverse transcriptase-based PCR (RT-PCR) was done for IGF2 on RNA extracted from RMS, RCC, and PB. These products were excised and eluted out from gel, then an aliquot was used for endonuclease digestion and nested PCR.
Messenger RNA in situ hybridizatiom. A 534 bp IGF2 cDNA fragment subcloned into pGEM-3 was labeled with digoxigenin-UTP and was used as sense and anti-sense RNA probes. Sample preparation and hybridization were done as described previously (Yun, 1993) .
RESULTS
Chromosome analysis
Both peripheral blood lymphocytes and RMS cells showed a normal 46,XY karyotype.
Southern blot analysis
Loss of heterozygosity (LOH) was observed at the TH locus in the RMS cells (Fig. 1) ; maternally-derived 2.8 and 2.0 kb fragments observed in leukocytes were absent in the RMS tissue. Southern analysis also showed maternal LOH in the IGF2 and INS loci (data not shown), while the other two loci (c-H-ras and DllS12) were not informative for polymorphisms in this family.
PCR analysis
Informative data were obtained in an RFLP at the IGF2 locus, a tetranucleotide repeat polymorphism (TNRP) at the TH locus and a dinucleotide repeat polymorphism (DNRP) at the DllS527 locus. The Apal-digest of IGF2/PCR product (primers, P2/P3) showed a homozygous pattern for the 231 bp/61 bp allele in the was digested with TaqI and hybridized with the tyrosine hydroxylase gene genomic probe, phins500. Father (F) was homozygous for a 4.8 kb fragment, mother (M) homozygous for 2.8 kb/2.0 kb bands, and the patient's leukocytes (PB) heterozygous for both alleles, while the rhabdomyosarcoma celt (RMS) was hemizygous for the 4.8 kb fragment. Fig. 2 . ApaI digested IGF2 PCR products (a). PCR products were digested with ApaI, separated on 6 70 polyacrylamide gel and stained with ethidium bromide (EtBr). Father (F) and mother (M) are homozygous for a 231 bp allele and for a 292 bp allele, respectively. Patient's peripheral leukocytes (PB), rhabdomyosarcoma (RMS), and renal tumor (RCC) are all heterozygous for both alleles, but the band intensity of the maternal allele in RMS is weak compared to that of PB or RCC. C, control, non-digested IGF2 product. Left lane shows a size marker. PCR products of TH (b). PCR products were electrophoresed on 6~ acrylamide gel and stained with EtBr. The band intensity of the maternal allele in RMS is reduced as in (a). father, a homozygous pattern for a 292 bp allele in the mother, and a heterozygous pattern for the two alleles in PB and RCC of the patient. In the RMS tissues, the intensity for the 292 bp maternally-derived allele was much low, compared with those in PB and RCC (Fig. 2a) . Similar findings were obtained in TH-TNRP (Fig. 2b) . At the DllS527 locus, the PCR products from each of the two tumor tissues showed an equal intensity between the maternal and paternal alleles (data not shown). Other polymorphisms, WT1/HinfI RFLP, WT1/3' dinucleotide (CA) repeat polymorphism, H19/RsaI, Alul, and HhaI RFLPs, H19-, WTI-, and INSSSCPs, were all uninformative in this family. The results of Southern blot and PCR analyses were summarized in Table 1 . The IGF2 RT-PCR product was digested with PstI or ApaI. PstI digests of 1,123 bp IGF2/RT-PCR products (primers, P1/P3) from each of RMS and RCC tissues gave 851, 351, and 21 bp fragments which coincided with the restriction map of the IGF2 cDNA. ApaI digestion revealed 892 and 231 bp fragments and a very weak 1,123 bp fragment from RMS. By nested PCR with primers P2/P3, 292 bp fragments were amplified from both of the tumors. ApaI digests gave 292, 231, and 61 bp fragments from RCC, while 292 bp fragment from RMS was very weak in intensity (Fig. 3, a, b, and c) . PB of the patient also revealed both of parental allele-derived transcripts (Fig. 3c) .
mRNA in situ hybridization
The IGF2 transcript was detected in moderate levels in the cytoplasm of the RMS cells, while the transcript was almost absent in the co-existing fibrous tissue of RMS and RCC and the surrounding normal renal tissue (Fig. 4) .
DISCUSSION
The frequency of complication of embryonal tumors is high in BWS patients, and rhabdomyosarcoma is the one of the associated tumors. It has been known that such an embryonal tumor tissue often shows LOH that involves loss of oncosuppressor gene(s). Southern blot and PCR analyses in the RMS from our BWS Fig. 3 . IGF2 RT-PCR products from rhabdomyosarcoma cells, a) IGF2 gene map and sites of primers (Pl 3) (a). P indicates PstI sites. Bi-directional arrow shows a polymorphic Apal site. RT-PCR and genomic PCR products from RMS tissue using primers P1 and P3 (b). c) P1/P3 RT-PCR products from RMS, RCC, and PB underwent nested PCR using primers P2/P3, then the products were digested by ApaI (c). RCC and PB showed both of parental allelederived transcripts, while maternal allele-derived transcript in RMS was weak in intensity. C, peripheral blood from normal control; m, size marker. patient showed maternal LOH at the TH, INS, and IGF2 loci all located to tlp15.5. As DllS12 at 11p15.5 and WT1 at llp13 were not informative in this family, we could not estimate a deletion extent on the chromosome 11 in the tumor cells. It seems less likely that the extent was large, because in the tumor tissue on visible deletion was seen by chromosome analysis. IGF2 expression is controlled by tissue-and development-specific ways. IGF2 has four different promoters and the use of each promoter seems to depend on different tissue-specific transcription factors (Sussenbach et al., 1992) . IGF2 is known to be maternally imprinted: only the paternally-derived allele is active, while the maternally-derived one is inactive during embryogenesis and also in one BWS patient (Ohlsson et al., 1993) . Recently, bi-allelic expression of H19 and 1GF2, namely, relaxation of imprinting or loss of imprinting (LOI) has been reported in Wilms tumor tissues, and the LOI may be causally related to tumorigenesis (Ogawa et al., 1993a , Rainier et al., 1993 . Because of LOH at llp15 in RMS of our patient, the tumor cell itself might express IGF2 only from paternally-derived allele, while both of parental alleles of 1GF2 were transcribed in RCC, leukocytes and probably in normal fibrous tissue of RMS. These results suggest that LOI might occur in the whole body in our patient and result in the occurrence of BWS. Very recently, LOI has been reported in some tissues including Wilms tumor of a patient with gigantism (Ogawa et al., 1993b) and in 4 of 6 BWS fibroblast strains (Weksberg et al., 1993) . Therefore, bi-alletic expression of IGF2 due to a mutation of a putative cis-or trans-acting element on maternally transmitted chromosome 11 which induces imprinting of IGF2, or paternal disomy of 1 lpl 5 might induce overexpression of IGF2 resulting in BWS. In this contex, H19 is very interesting, because it is located near the IGF2 locus (Zemel et al., 1992) and known to be imprinted inversely to IGF2 (Zhang and Tycko, 1992) . It might be associated with IGF2 imprinting, because it may function as the nuclear RNA (Brannan et al., 1990) , as in case of XIST on X chromosome inactivation (Brown et aL, 1991) . We could not elucidate the imprinting status of the H19 gene in either of the tumor tissues, since any H19 polymorphisms were uninformative in our family.
In situ hybridization revealed that the IFG2 transcript in the tissue level was moderate in RMS cells but almost nil in RCC and the fibrous tissue of RMS, although both parental IGF2 alleles were expressed on RT-PCR analysis. Renal cell carcinoma is derived from the renal epithelium in which IGF2 expression is absent even in the fetal kidney (Yun, 1993) . These data suggest that bi-allelic expression of IGF2 itself might not mean increased expression of IGF2, nor induce tumor occurrence and/or progression, especially in tissues where IGF2 is not usually expressed and/or when IGF2 expression is developmentally regressed. The increased expression of 1GF2 in some tissues may influence the growth of tumor(s). It is known that 1GF2 expression is increased in some tumor tissues including embryonal tumors (Sussenbach et al., 1992) . In some tumors involving LOH at llp15, loss of the function of a putative onco-suppressor gene at 1 lpl 5 (Koi et al., 1993) might induce the tumor occurrence and progression. Therefore, the constitutional bi-allelic expression of IGF2 may cause somatic overgrowth, which predisposes to tumorigenic mutations (Chao et al., 1993) and/or rapid growth of tumor by the IGF2 autocrine mechanism.
Our patient developed two different neoplasms, RMS and RCC, in a short period. These two tumors might have occurred through different mechanisms of tumorigenesis, because the LOH of chromosome 1 lp was seen in RMS but not in RCC. The former was likely associated to BWS, whereas a mechanism of the occurrence of the latter remained unknown but could be associated to irradiation and/or chemotherapy as in the case of Banner et al. (1977) or to other gene abnormality such as a putative onco-suppressor gene on chromosome 3p (Knudson, 1993) .
